Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.

Use of antiparkinsonian medication tied to acquired premature ejaculation

06 Jun 2018

Individuals taking antiparkinsonian drugs have developed ejaculatory dysfunction, which suggests a possible medication effect, in a case series of Parkinson’s disease (PD) patients with acquired premature ejaculation (PE).

The mean age of PD onset was 53.3±12.7 years (range, 38–77 years), while sexual problems started to appear 4.0±3.1 years later. Patients had a mean 7.3 min (range, 2–20 min) of intravaginal ejaculation latency (IELT) before the onset of acquired PE.

Of note, there was an abrupt appearance of the ejaculatory dysfunction as characterized by a dramatically shortened IELT in all patients. Furthermore, three patients had an ejaculation prior to vaginal penetration, which hampered sexual intercourse.

In some patients, two additional sexual problems occurred: four had erectile dysfunction, five had libido changes, four had increase desire and one had reduced desire.

In this study, the investigators described eight PD patients who asked for a sexological consultation between 2008 and 2014 because of new-onset of PE. Patients were diagnosed with acquired PE according to the DSM-V criteria and the International Society for Sexual Medicine committee. Demographic, medical and sexual-related data of patients were retrieved and analysed.

Acquired PE is defined as “a male sexual dysfunction characterized by the development of a clinically significant and bothersome reduction in ejaculation latency time in men with previous normal ejaculatory experiences, often to about 3 minutes or less, the inability to delay ejaculation on all or nearly all vaginal penetrations, and the presence of negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.” [Transl Androl Urol 2016;5:434-449]

“PE has been reported in 40.6–51.5 percent of men affected by PD,” the investigators said. “However, this nonmotor sexual complaint has not been studied in detail.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.